by Molecular Therapy Advances
Scientists believe lentiviral (LV)-based virus-like particles (VLPs) could improve chimeric antigen receptor (CAR) T-cell therapies and enable rapid, scalable production of gene-edited CAR T-cells...
by Blood
Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 and CD70 has the potential to improve outcomes in individuals with follicular lymphoma (FL) who have elevated relapse risk.
by Transplantation and Cellular Therapy
Graft-versus-host disease (GVHD) and non-relapse mortality (NRM) are possible after allogeneic hematopoietic cell transplantation (allo-HCT), but researchers say a recipient's pre-procedure...
by British Journal of Haematology
Results from a retrospective investigation identified deletion (13q)/monosomy 13 (del[13q]/-13) as an independent risk factor for poor outcomes in multiple myeloma (MM) patients receiving upfront...
by Alex Kadhim
New findings from the RESET-PV study suggest CD19 CAR-T therapy may be effective in pemphigus vulgaris without lymphodepleting chemotherapy, demonstrating clinical responses, B-cell depletion, and...
by Alex Kadhim
A comparative analysis of the FELIX trial suggests obecabtagene autoleucel (obe-cel) may improve remission rates, event-free survival, and overall survival compared with historical standard...